IDYA

$31.33-0.98%visit website

IDEAYA Biosciences, Inc.

Market Cap

$3.0B

Live price × SEC shares (Oct 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.07

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

82.9

TTM to Sep 2026 · revenue

P/B

2.8

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	10,876	6,560	8,857	10,242	36,535
Research & development	86,599	95,726	82,993	121,576	386,894
Total operating expenses	105,446	115,104	131,148	147,874	499,572
Operating income	(94,570)	(108,544)	(122,291)	(137,632)	(463,037)
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(83,273)	(98,539)	(112,452)	(125,749)	(420,013)
EPS (basic) ($)		(1.11)	(1.22)	(1.22)	(4.50)
EPS (diluted) ($)		(1.11)	(1.22)	(1.22)	(4.50)
Weighted avg. shares (basic)		88,700	92,061	102,944
Weighted avg. shares (diluted)		88,700	92,061	102,944

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 3, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 31 more quarters, back to Mar 2018, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 3, 2026 accepted 8:04 AM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

31%

W/W -19.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

23.98x

Avg Daily Selling (90d)

293 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-06	2026-10-08	Hata Yujiro S	Director & President and CEO	Sale	26.3K	$37.41	$985K	690.7K	View
2026-07-07	2026-07-09	Ruiz Briseno Andres	Chief Accounting Officer	Sale	9,550	$40.01	$382K	26.5K	View
2026-03-02	2026-03-02	Stein Jeffrey	Director	Purchase	50.0K	$32.96	$1.65M	54.3K	View

Recent News

IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-03

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

Yahoo · 2026-11-03

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

Yahoo · 2026-11-03

A drug for eye melanoma showed a 57% eye-preservation rate in one trial group

Stock Titan · 2026-11-03

IDEAYA Biosciences Q3 EPS $(1.22) Misses $(1.18) Estimate, Sales $10.242M Beat $6.857M Estimate

Benzinga · 2026-11-03

Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Yahoo · 2026-11-02

Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?

Yahoo · 2026-10-31

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-10-30

Four new IDEAYA hires get options to buy shares at $32.89 each

Stock Titan · 2026-10-30

Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

Yahoo · 2026-10-28

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Yahoo · 2026-10-27

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

Yahoo · 2026-10-23

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

Yahoo · 2026-10-21

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma

Yahoo · 2026-10-19

IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress

Benzinga · 2026-10-19

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-10-06	Hata Yujiro S	S	25,538	$954,786.65
2026-10-06	Hata Yujiro S	S	800	$30,610.08
2026-07-07	Ruiz Briseno Andres	S	9,550	$382,130.84
2026-03-02	Stein Jeffrey	P	50,000	$2M

IDYA

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

IDEAYA Biosciences, Inc. (IDYA)

Reporting Insiders

Factor Profile

Corporate Events (8-K)